Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2931682 | 0.77 | CYP3A4 (0.30) | CYP3A4 | |
| SCHEMBL5736563 | 0.70 | LMNA (0.54) | LMNACYP3A4ACHEALDH1A1KMT2A | |
| SCHEMBL2936904 | 0.60 | LMNA (0.40) | LMNACYP3A4ACHEKMT2AMEN1 | |
| SCHEMBL249305 | 0.60 | LMNA (0.76) | LMNACYP3A4ACHEALDH1A1KMT2A | |
| SCHEMBL17028900 | 0.60 | LMNA (0.76) | LMNACYP3A4ACHEALDH1A1KMT2A | |
| SCHEMBL5743614 | 0.59 | LMNA (0.63) | LMNACYP3A4ACHEALDH1A1KMT2A | |
| SCHEMBL26564348 | 0.58 | LMNA (0.61) | LMNACYP3A4ACHEALDH1A1KMT2A | |
| SCHEMBL13259617 | 0.58 | CYP3A4 (0.49) | LMNACYP3A4CACNA1BAPBA1ACHE | |
| SCHEMBL280618 | 0.58 | LMNA (1.00) | LMNACYP3A4ACHEALDH1A1KMT2A | |
| SCHEMBL30638434 | 0.58 | LMNA (1.00) | LMNACYP3A4ACHEALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501819-B1 | ESTROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2010-09-15 | — | — | EP | disclosed |
| US-7138426-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2006-11-21 | — | — | US | disclosed |
| EP-1501819-A4 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050234245-A1 | Estrogen receptor modulators | MERCK SHARP & DOHME CORP. | 2005-10-20 | — | — | US | disclosed |
| EP-1501819-A1 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003091239-A1 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234245-A1 | Estrogen receptor modulators | ESRRB, ESR2, GPER1 | LMNA 873/4885CYP3A4 2328/4885CACNA1B 3129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.